Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain

Journal of Chemical Neuroanatomy

Volumn 21, Issue 4, 2001, Pages 277-288

  Chauhan, Neelima B ^a,b   Siegel, George J ^a,b   Lee, John M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Aging; Dopaminergic neurons; Image analysis; Immunocytochemistry; Neuronal loss; Neurotrophic factors; Parkinson's disease; Substantia nigra

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROMELANIN; NEUROTROPHIN 3; NEUROTROPHIN 4; NEUROTROPIC AGENT;

AGED; ARTICLE; BRAIN NERVE CELL; CASE REPORT; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NERVE CELL DEGENERATION; NEUROPIL; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEPLETION; SUBSTANTIA NIGRA; TISSUE LEVEL;

AGED; BLOTTING, WESTERN; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0034959811     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-0618(01)00115-6     Document Type: Article

References (45)

1. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
2. TrkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: An in situ hybridization study
3. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations
4. A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy
5. PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome
6. GDNF is an age-specific survival factor for sensory and autonomic neurons
7. Differential expression of Na,K-ATPase α1- and α3-mRNAs in aging rat cerebellum
8. Reductions in glial cell line-derived neurotrophic factor (GDNF) in the surviving neurons of substantia nigra in Parkinson's disease
9. Selective depletion of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease
10. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system
11. A Drosophila model of Parkinson's disease
12. Functional recovery in Parkinsonian monkeys treated with GDNF
13. Glial cell line-derived neurotrophic factor (GDNF): A drug candidate for the treatment of Parkinson's disease
14. Tyrosine hydroxylase and Parkinson's disease
15. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems
16. Immunocytochemical localization of GDNF in primary afferents of the lumbar dorsal horn
17. The intermolecular disulfide bridge of human glial cell line-derived neurotrophic factor: Its selective reduction and biological activity of modified protein
18. Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: A post mortem in situ hybridization study with special reference to Parkinson's disease
19. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
20. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate model of Parkinson's disease
21. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor
22. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
23. Trophic protection of motor neurons: Clinical potential in motor neuron diseases
24. Glial cell-line derived neurotrophic factor prevents death, but not the reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats
25. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations
26. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
27. Intrastriatal infusions of brain-derived neurotrophic factor: Retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat
28. Distribution and retrograde transport of trophic factors in the central nervous system: Functional implications for the treatment of neurodegenerative diseases
29. Medial nigral dopamine neurons have rich neurotrophin support in humans
30. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra
31. Trauma-induced striatal CNTF and BDNF-mRNA in hemiparkinsonian rats
32. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
33. Regional and cell-specific expression of GDNF in rat brain
34. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
35. +)-adenosinetriphosphatase catalytic subunit doublets
36. Neurotrophic factors in Alzheimer's and Parkinson's disease brain
37. Expression of GDNF mRNA in rat and human nervous tissue
38. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease
39. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
40. Maintaining the neuronal phenotype after injury in the adult CNS
41. Growth factors in Parkinson's disease
42. Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease
43. GDNF: A novel factor with therapeutic potential for neurodegenerative disorder
44. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease
45. Growth factors rescue embryonic dopaminergic neurons from programmed cell death